We have previously reported on the efficacy of intraperitoneal (i.p.)immunotherapy with interleukin-2 (IL-2) and adoptively transferred lymphokine activated killer (LAK) cells in an i.p. murine tumour model. Here, IL2 is linked to neoplasm.